Investing Profile

Hakan Goker

InvestorVC
Managing Director at M Ventures (Merck)
m-ventures.com/enAmsterdam, Netherlands
Photo of Hakan Goker, Managing Director at M Ventures (Merck)

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
M Ventures (Merck) Managing Director
$100K - $5.0M
$1.5M
20
€600M
CompanyStageDateRound SizeTotal Raised
TRIMTECH Therapeutics
SeedMar 2025$31M
$31M
Co-investors: Michael Anstey (Cambridge Innovation Capital), Jeffrey Moore (MP Healthcare Venture Management), Laurence Barker (SV Health Investors)
Asceneuron
Series CJul 2024$100M
Series ASep 2015$31M
$130M
Co-investors: Philip Scheltens (EQT Life Sciences), Henrijette Richter (Soffinova Partners)
iOnctura
Series BJun 2024$86M
Series AJul 2020$6M
Series AJan 2020$17M
SeedJun 2017
$110M
Co-investors: Roel Bulthuis (INKEF Capital), Keno Gutierrez (BGV (BioGeneration Ventures)), Fiona MacLaughlin (Johnson & Johnson Innovation)
Nouscom
Series CNov 2023$73M
$140M
Co-investors: Scott Rocklage (5am Ventures), Guido Magni (Versant Ventures), Joachim Rothe (EQT Life Sciences), Genghis Lloyd-Harris (Abingworth), Sofia Ioannidou (Andera Partners)
Storm Therapeutics
Series BDec 2022$30M
Series AMay 2019$18M
Series AJun 2016$16M
$69M
Co-investors: Sakae Asanuma (Taiho Ventures), Bruno Montanari (Seroba Life Sciences)
Artios Pharma
Series CJul 2021$150M
Series ASep 2016$33M
$270M
Co-investors: Raphael Wisniewski (Andera Partners), Barbara Dalton (Pfizer Venture Investments), René Kuijten (EQT Life Sciences), Florian Müllershausen (Novartis Venture Fund)
Forendo Pharma
Series UnknownJul 2019$6M
Series UnknownSep 2018$5M
Series AOct 2014$15M
$26M
Co-investors: Anja Konig (Novartis Venture Fund)
Ribometrix
Series ANov 2018$30M
$38M
Co-investors: John Gustofson (AbbVie Ventures), Mike Dial (Hatteras Venture Partners)